944258-72-4

Usage

Uses

Used in Pharmaceutical Industry:
5-Azaspiro[2.4]heptan-7-ol is used as a reactant in the preparation of N-[3-(quinolin-6-yl)pyridin-5-yl] benzenesulfonamides. These compounds serve as PI3 kinase modulators, which are important in the development of targeted therapies for various diseases, including cancer. By modulating the activity of PI3 kinase, these benzenesulfonamides can potentially influence cellular processes and contribute to the treatment of specific conditions.

Upstream product

• 1221443-39-5 5-((R)-α-methylbenzyl)-7-hydroxy-5-azaspiro[2.4]heptane 
• 32933-03-2 ethyl 1-acetylcyclopropanecarboxylate 
• 129306-05-4 ethyl 1-(2-bromoacetyl)cyclopropanecarboxylate 
• 127199-37-5 4,7-dioxo-5-<1(R)-phenylethyl>-5-azaspiro<2.4>heptane 
• 129306-04-3 5-benzyl-5-azaspiro[2.4]heptane-4,7-dione 

Downstream Products

• 1221443-13-5 N'-(4-(7-(3-(7-hydroxy-5-azaspiro[2.4]heptane-5-yl)propoxy)-6-methoxyquinolin-4-yloxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1221442-95-0 N-(4-(7-(3-(7-hydroxy-5-azaspiro[2.4]heptane-5-yl)propoxy)-6-methoxyquinolin-4-yloxy)-3-fluorophenyl)-2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazole-4-carboxamide 
• 1221443-01-1 N'-(4-(7-(3-(7-hydroxy-5-azaspiro[2.4]heptane-5-yl)propoxy)-6-methoxyquinolin-4-yloxy)-3-fluorophenyl)-N-phenylcyclopropane-1,1-dicarboxamide 
• 1221442-96-1 N-(4-(7-(3-(7-hydroxy-5-azaspiro[2.4]heptane-5-yl)propoxy)quinolin-4-yloxy)-3-fluorophenyl)-2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazole-4-carboxamide 
• 1221442-98-3 N-(5-(7-(3-(7-hydroxy-5-azaspiro[2.4]heptane-5-yl)propoxy)-6-methoxyquinolin-4-yloxy)pyridin-2-yl)-2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazole-4-carboxamide 
• 1221442-99-4 N'-(4-(7-(3-(7-hydroxy-5-azaspiro[2.4]heptane-5-yl)propoxy)quinolin-4-yloxy)-3-fluorophenyl)-N-phenylcyclopropane-1,1-dicarboxamide 
• 1221443-14-6 N'-(5-(7-(3-(7-hydroxy-5-azaspiro[2.4]heptane-5-yl)propoxy)-6-methoxyquinolin-4-yloxy)pyridin-2-yl)-N-phenylcyclopropane-1,1-dicarboxamide 
• 1221442-97-2 N-(5-(7-(3-(7-hydroxy-5-azaspiro[2.4]heptane-5-yl)propoxy)quinolin-4-yloxy)pyridin-2-yl)-2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazole-4-carboxamide 
• 1221443-00-0 N'-(5-(7-(3-(7-hydroxy-5-azaspiro[2.4]heptane-5-yl)propoxy)quinolin-4-yloxy)pyridin-2-yl)-N-phenylcyclopropane-1,1-dicarboxamide 

Relevant academic research and scientific papers

Having a spiro ring substituent of aryl morpholine compound, its preparation and use

The invention discloses arylmorpholine compounds with spiro substituents. The arylmorpholine compounds are compounds having the following general formula (I), wherein X is N or CH; R1 is hydrogen, hydroxyl, alkoxy, halogen, amino, amido, acylamino, sulfam

AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE

The present invention provides amino ester compounds, salts, and pharmaceutical formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

COMPOUNDS AND METHODS OF USE

The present invention provides novel compounds useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE

The present invention provides amino ester compounds, salts, and pharmaceutical formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Spiro compounds and methods of use

The present invention relates to spiro compounds of formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states such as cancers associated with protein tyrosine kinases, especially epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF), to their method of use as medicaments and to their method of use in the manufacture of medicaments for use in the production of inhibition of tyrosine kinase reducing effects in warm-blooded animals such as humans.